Another Big Week for RNAi Therapeutics
Insights - Arrowhead Research (ARWR) raised as many questions as it answered this week when the company reported interim results from a mid-stage study of hepatitis B drug … Continue Reading
Read NowInsights
Arrowhead: All Eyes on November Medical Meeting
Insights - On Tuesday evening, Arrowhead Research (ARWR) released the first human results for its experimental therapeutic ARC-520 in hepatitis B along with its second quarter financial results. Though not … Continue Reading
Read NowIntercept Pharma Back in Favor on Updated FLINT Results
Insights - Investors are again infatuated with Intercept Pharmaceuticals (ICPT), which on Monday reported further results from a mid-stage study of drug candidate obeticholic acid. ICPT rocketed higher by 400% … Continue Reading
Read Now
Tekmira STILL Getting Love on Ebola Hype
Insights - In which we suggest taking profit and/or selling Calls on TKMR equity position. A handy return from $11.50 in July.
Read NowARIAD Misses Wall Street Expectations
Insights - Investors and analysts expected more out of Ariad Pharmaceuticals’ (ARIA) Iclusig in the second quarter and punished the stock when sales from the company’s only … Continue Reading
Read Now
Regeneron Slips in Pre-Market after Strong Sales Report
Insights - Despite encouraging quarterly U.S. sales from its Eylea treatment for macular degeneration, reported on Tuesday morning, Regeneron Pharmaceuticals’ (REGN) shares were down more than two … Continue Reading
Read NowThis Week’s Small-Cap Healthcare Roundup
Insights - Tekmira Pharmaceuticals (TKMR) was the momentum stock of the week as the spread of Ebola continues in Guinea, Liberia and Sierra Leone, and two infected Americans … Continue Reading
Read Now